Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Molecular and Cellular Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1531465
This article is part of the Research Topic Formation of Immunological Niches in Tumor Microenvironments: Mechanisms and Therapeutic Potential View all 16 articles

The aggrephagy-related gene TUBA1B influences clinical outcomes in glioma patients by regulating the cell cycle

Provisionally accepted
Zesheng Sun Zesheng Sun 1Pengcheng Huang Pengcheng Huang 2*Jialiang Lin Jialiang Lin 1*Guiping Jiang Guiping Jiang 1*Jian Chen Jian Chen 1Qianqian Liu Qianqian Liu 1*
  • 1 Nantong University, Nantong, China
  • 2 Tianjin Medical University, Tianjin, Tianjin Municipality, China

The final, formatted version of the article will be published soon.

    Background: Gliomas are common primary malignant brain tumors, with glioblastoma (GBM) being the most aggressive subtype. GBM is characterized by high recurrence rates and treatment resistance, leading to poor patient outcomes. Current prognostic models have limited predictive power, underscoring the need to elucidate underlying mechanisms and identify novel biomarkers to improve therapeutic strategies and prognostic models.Methods: Gene expression and clinical data for GBM and LGG were obtained from the TCGA and CGGA database, while single-cell sequencing data from GSE167960 were selected from the GEO database. Molecular characteristics of gliomas were revealed through normalization, consensus clustering analysis, immune scoring, cell infiltration analysis, and pathway analysis. TUBA1B, identified as a key gene through machine learning, was incorporated into a nomogram model using multivariate Cox regression. Its functions were validated through qRT-PCR, in vitro functional assays, and mouse xenograft models. All data analyses and statistics were performed using R software.Results: Consensus clustering of the TCGA glioma dataset identified two aggrephagy subtypes (C1 and C2), with C2 showing worse survival outcomes and higher immune infiltration. TUBA1B was identified as an independent prognostic marker, with high expression associated with upregulated cell cycle pathways and alterations in the immune microenvironment. TUBA1B was shown to influence glioma cell proliferation, migration, invasion, and autophagy, impacting tumor progression and treatment response through intercellular communication and metabolic pathways.The study demonstrates that high TUBA1B expression is closely associated with glioma malignancy and poor prognosis, making it a potential therapeutic target.

    Keywords: Glioma, Aggrephagy, TUBA1B, prognostic marker, immune microenvironment

    Received: 20 Nov 2024; Accepted: 04 Feb 2025.

    Copyright: © 2025 Sun, Huang, Lin, Jiang, Chen and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Pengcheng Huang, Tianjin Medical University, Tianjin, 300070, Tianjin Municipality, China
    Jialiang Lin, Nantong University, Nantong, China
    Guiping Jiang, Nantong University, Nantong, China
    Qianqian Liu, Nantong University, Nantong, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.